-
Vumerity Shown to Decrease RRMS Disease Activity
The results of a recent clinical trial show that Vumerity (diroximel fumarate) significantly decreased the disease activity in relapsing-remitting MS patients. Read more about the trial and its findings here.
What are your thoughts about this news?
Sorry, there were no replies found.
Log in to reply.